News
![DGAP-News: CytoTools AG: Außerordentliche Hauptversammlung der CytoTools AG vom 18.11.21 stimmt mit 88% für Kapitalerhöhung - klarer Fokus auf die Finanzierung der internationalen Zulassung von DermaPro(R)](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
DGAP-News: CytoTools AG: Außerordentliche Hauptversammlung der CytoTools AG vom 18.11.21 stimmt mit 88% für Kapitalerhöhung - klarer Fokus auf die Finanzierung der internationalen Zulassung von DermaPro(R)
![DGAP-News: Burcon nimmt an bevorstehenden Investorenkonferenzen teil](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
DGAP-News: Burcon nimmt an bevorstehenden Investorenkonferenzen teil
![DGAP-News: Burcon to Participate in Upcoming Investor Conferences](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
DGAP-News: Burcon to Participate in Upcoming Investor Conferences
![Pharnext appoints Dr. Burkhard Blank as new Chief Medical Officer and Head of Research & Development](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Pharnext appoints Dr. Burkhard Blank as new Chief Medical Officer and Head of Research & Development
![Advanced Auto Parts Stock May be Cheap for a Reason: https://www.marketbeat.com/logos/articles/med_20240826073705_advanced-auto-parts-stock-may-be-cheap-for-a-reaso.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBekVEYlE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--7b6e1d69ff2a2944b6d3405d05491854049737de/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240826073705_advanced-auto-parts-stock-may-be-cheap-for-a-reaso.jpg?locale=us)
Advanced Auto Parts Stock May be Cheap for a Reason
Advanced Auto Parts Inc. (NYSE: AAP) stock fell 3.8% on August 23, the day after the company reported significantly lower profits than analysts expected in the company's second quarter 2024
![Biotech Stock Soars 60% in 2024: Cathie Wood’s Bold Investment: https://www.marketbeat.com/logos/articles/med_20240823074150_cathie-wood-has-90-million-in-this-ai-precision-me.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBem9CYlE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--0645ea02ca855c783b16dbe55ceeb8897ebab0ea/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240823074150_cathie-wood-has-90-million-in-this-ai-precision-me.jpg?locale=us)
Biotech Stock Soars 60% in 2024: Cathie Wood’s Bold Investment
In just ten days, shares of the mid-cap healthcare stock Tempus AI (NASDAQ: TEM) have gone from down 4% to up nearly 60% in 2024. Famed investor Cathie Wood recently increased her allocation to
![Diabetes and Neuro Products Ignite Medtronic’s Q1 Earnings Rally: https://www.marketbeat.com/logos/articles/med_20240822125851_diabetes-and-neuro-products-ignite-medtronics-q1-e.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeWdCYlE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e0a2419874d096ead653c2a284ad88371c3d1806/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240822125851_diabetes-and-neuro-products-ignite-medtronics-q1-e.jpg?locale=us)
Diabetes and Neuro Products Ignite Medtronic’s Q1 Earnings Rally
Shares of medical device manufacturer Medtronic PLC (NYSE: MDT) are down about 35% from their highs of roughly three years ago, but promising results from the company's first quarter of fiscal
![Value Investing: Unearthing 3 Hidden Gems in Today's Market: https://www.marketbeat.com/logos/articles/med_20240820115034_value-investing-unearthing-hidden-gems-in-todays-m.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOEgrYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--b984b3905a5099682b114d8e0912af8064f61736/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240820115034_value-investing-unearthing-hidden-gems-in-todays-m.jpg?locale=us)
Value Investing: Unearthing 3 Hidden Gems in Today's Market
During times of market volatility and concerns about overvaluation, investors are increasingly turning to time-tested strategies to navigate the complexities of the stock market. Among these
![The First Half of 2025 Will Be a Massive Test for AST SpaceMobile: https://www.marketbeat.com/logos/articles/med_20240820113636_the-first-half-of-2025-will-be-a-massive-test-for.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOEwrYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--98f993a5edd9c594b37d46414b9f35c13804282a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240820113636_the-first-half-of-2025-will-be-a-massive-test-for.jpg?locale=us)
The First Half of 2025 Will Be a Massive Test for AST SpaceMobile
AST SpaceMobile (NASDAQ:ASTS) is in the communication services sector and has seen its shares explode in 2024. The company’s stock is up over 500% this year despite producing little to no
![Merck's Stock Dip Offers a Buying Opportunity: Here’s Why: https://www.marketbeat.com/logos/articles/med_20240819101736_chartb-mrk.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNjM5YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--59143572078822ceed66024d556063fae60b2511/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240819101736_chartb-mrk.jpg?locale=us)
Merck's Stock Dip Offers a Buying Opportunity: Here’s Why
Global big pharmaceutical company Merck & Co. Inc. (NYSE: MRK) shares sank 9% following its Q2 2024 earnings release. Merck beat top and bottom line estimates, but the lowered full-year EPS 2024
![This Early-Stage Biotech Stock Is Up 400% — Should You Buy Now?: https://www.marketbeat.com/logos/articles/med_20240816144216_this-early-stage-biotech-stock-is-up-400-should-yo.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMi84YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--07a803ac6b10b52b964ef902da3341d5b39aa460/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240816144216_this-early-stage-biotech-stock-is-up-400-should-yo.jpg?locale=us)
This Early-Stage Biotech Stock Is Up 400% — Should You Buy Now?
Avidity Biosciences (NASDAQ: RNA) is a biopharmaceutical stock focusing on RNA therapeutics. The company’s stock is up around 400% so far in 2024.
However, even with this massive appreciation
![3 Stocks to Buy for a Soft Landing, If There Is One: https://www.marketbeat.com/logos/articles/med_20240815092649_3-stocks-to-buy-for-a-soft-landing-if-there-is-one.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNmo1YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--c66f1006d9160283786cdffff5162f23b744f556/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240815092649_3-stocks-to-buy-for-a-soft-landing-if-there-is-one.jpg?locale=us)
3 Stocks to Buy for a Soft Landing, If There Is One
Recent economic data is reigniting talk about a soft landing for the economy. That means that the Federal Reserve’s monetary policy regarding interest rates is neither too restrictive nor too
![Defying the Market: 3 Mega-Cap Stocks Soaring to New Highs: https://www.marketbeat.com/logos/articles/med_20240814092658_defying-the-market-3-mega-cap-stocks-soaring-to-ne.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMnY0YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--37abdc902514aea4e8315b1cc9b6b58e29c95618/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240814092658_defying-the-market-3-mega-cap-stocks-soaring-to-ne.jpg?locale=us)
Defying the Market: 3 Mega-Cap Stocks Soaring to New Highs
In a market characterized by uncertainty and volatility, it's increasingly rare to find stocks that are weathering the storm and thriving. Yet, a select few from various sectors are doing just
![MedMira startet Klinische Tests mit Multiplo® Complete Syphilis (TP/nTP) Antibody Test - ein möglicher Game Changer um die Syphilis-Gesundheitskrise in Kanada zu meistern: https://www.irw-press.at/prcom/images/messages/2024/76536/MedMira_14082024_DEPRcom.001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK1AzYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ce57811465e30c4768b51785101037d833a388c5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/MedMira_14082024_DEPRcom.001.png?locale=us)
MedMira startet Klinische Tests mit Multiplo® Complete Syphilis (TP/nTP) Antibody Test - ein möglicher Game Changer um die Syphilis-Gesundheitskrise in Kanada zu meistern
Halifax, Nova Scotia, 13. August 2024 - MedMira Inc. (MedMira) (TSXV: MIR) gibt mit Freude bekannt, dass es vollständige klinische Studien für seinen einzigartigen Multiplo® Complete
![Clinical Trials to get Underway with Multiplo® Complete Syphilis (TP/nTP) Antibody Test - A Potential Game Changer to Address Syphilis Health Crisis in Canada: https://www.irw-press.at/prcom/images/messages/2024/76536/MedMira_14082024_ENPRcom.001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK1QzYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--f80e005bca5f579dfdc1507d54fb56b33d4cf2e2/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/MedMira_14082024_ENPRcom.001.png?locale=us)
Clinical Trials to get Underway with Multiplo® Complete Syphilis (TP/nTP) Antibody Test - A Potential Game Changer to Address Syphilis Health Crisis in Canada
Halifax, Nova Scotia, 13 August, 2024 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces it will conduct full clinical trials for its unique Multiplo® Complete Syphilis (TP/nTP) Antibody
![Der Modern Data Quality Summit 2024 von DQLabs ebnet den Weg zu KI-Bereitschaft: https://www.irw-press.at/prcom/images/messages/2024/76530/DQLabs_081324_DEPRcom.001.jpeg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMm4zYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--4a6cf013b44eb06aa8ecb9747baad2d04f268112/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/DQLabs_081324_DEPRcom.001.jpeg?locale=us)
Der Modern Data Quality Summit 2024 von DQLabs ebnet den Weg zu KI-Bereitschaft
Hochwertige Daten, intelligente KI - Sie sind so bereit für KI wie Ihre Daten
PASADENA, KALIFORNIEN / ACCESSWIRE / 13. August 2024 / DQLabs, das Unternehmen für moderne Data Quality und
![DQLabs Modern Data Quality Summit 2024 Accelerates Path to AI-Readiness: https://www.irw-press.at/prcom/images/messages/2024/76530/DQLabs_081324_ENPRcom.001.jpeg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMnYzYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--b34cbc9a19da6c1e6fce60bcd2b6617665f07b13/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/DQLabs_081324_ENPRcom.001.jpeg?locale=us)
DQLabs Modern Data Quality Summit 2024 Accelerates Path to AI-Readiness
Quality Data, Smart AI - You are as AI-Ready as Your Data
PASADENA, CA / ACCESSWIRE / August 13, 2024 / DQLabs, the Modern Data Quality and Observability company is hosting the Modern Data
![Novavax Plunges on Earnings Miss: Falling Knife or Buying Opp?: https://www.marketbeat.com/logos/articles/med_20240811162653_chartx-nvax.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOXIxYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--b8dc2dd5960ba1ee1e9df8844ca8113c11a40945/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240811162653_chartx-nvax.jpg?locale=us)
Novavax Plunges on Earnings Miss: Falling Knife or Buying Opp?
Novavax Inc. (NASDAQ: NVAX) is a biotechnology company that focuses on developing and commercializing vaccines for serious infectious diseases. Its most significant vaccine, Nuvaxovid, is for COVI
![MicroVision meldet die Ergebnisse des zweiten Quartals 2024: https://www.irw-press.at/prcom/images/messages/2024/76468/MicroVisionNR08072024_DE_PRcom.003.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBei94YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--757a8ba4601f12c639af1c96b934bbf845221d07/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/MicroVisionNR08072024_DE_PRcom.003.png?locale=us)
MicroVision meldet die Ergebnisse des zweiten Quartals 2024
REDMOND, WA / ACCESSWIRE / 7. August 2024 / MicroVision, Inc. (NASDAQ:MVIS), ein führender Anbieter von MEMS-basierten Festkörper-Automobil-LiDAR- und modernen Fahrerassistenzlösungen (ADAS),
![MicroVision Announces Second Quarter 2024 Results: https://www.irw-press.at/prcom/images/messages/2024/76468/MicroVisionNR08072024_PRcom.003.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMER4YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3ba16110f49112effacc958baac4ce5ac9bb286d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/MicroVisionNR08072024_PRcom.003.png?locale=us)
MicroVision Announces Second Quarter 2024 Results
REDMOND, WA / ACCESSWIRE / August 7, 2024 / MicroVision, Inc. (NASDAQ:MVIS), a leader in MEMS-based solid-state automotive lidar and ADAS solutions, today announced its second quarter 2024
![Amgen's MariTide Weight Loss Potential: Stock Outlook: https://www.marketbeat.com/logos/articles/med_20240807084756_amgens-maritide-weight-loss-potential-stock-outloo.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMmJ3YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--f8661f74d450e513993c46eccb7ecc5e4a54bad1/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240807084756_amgens-maritide-weight-loss-potential-stock-outloo.png?locale=us)
Amgen's MariTide Weight Loss Potential: Stock Outlook
Amgen (NASDAQ: AMGN) is a biotechnology firm that has made its way into the weight loss treatment battle. The company’s shares have performed relatively well in 2024, providing a total return of
![Why AST SpaceMobile Stock is a Must-Watch in 2024: https://www.marketbeat.com/logos/articles/med_20240806145404_ast-spacemobile-nears-launch-of-direct-to-satellit.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeGp3YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--84f3703660edf8c8a1475fe565b64c2830fa6b40/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240806145404_ast-spacemobile-nears-launch-of-direct-to-satellit.jpg?locale=us)
Why AST SpaceMobile Stock is a Must-Watch in 2024
AST SpaceMobile Inc. (NASDAQ: ASTS) is a little-known satellite company with ambitious plans to create the world's first and only space-based cellular broadband network. The goal is to enable
![Medical Technology Stock Benefits from Rising Acute Care Demand: https://www.marketbeat.com/logos/articles/med_20240804190513_chartg-syk.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeHJ3YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--8f594e76b514dc585587c3092fa14586fececce4/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240804190513_chartg-syk.jpg?locale=us)
Medical Technology Stock Benefits from Rising Acute Care Demand
Medical and surgical products manufacturer Stryker Co. (NYSE: SYK) is a beneficiary of the acute care boom occurring in the healthcare industry. Acute care is considered short-term intensive
![Humana Slides on Profitability Concerns Despite Q2 Earnings Beat: https://www.marketbeat.com/logos/articles/med_20240801073139_humana-slides-on-profitability-concerns-despite-q2.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNFBwYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--6cab1205557bb7b7a49eb3b07aef32f689be90f2/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240801073139_humana-slides-on-profitability-concerns-despite-q2.jpg?locale=us)
Humana Slides on Profitability Concerns Despite Q2 Earnings Beat
Humana Inc. (NYSE: HUM) is a leading health insurer predominantly focused on Medicare Advantage plans, serving millions of individuals and families nationwide. The company's business model centers
![AbbVie Analysts Lead the Stock Higher as Humira Worries Recede: https://www.marketbeat.com/logos/articles/med_20240730104221_chart-abbv-7303034.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNHZtYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--35b89d873153e1f089b95f53e8fe2a230988c29a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240730104221_chart-abbv-7303034.png?locale=us)
AbbVie Analysts Lead the Stock Higher as Humira Worries Recede
AbbVie (NYSE: ABBV) was among the pharma companies worst positioned for a patent cliff that has come and gone. However, management's lean toward diversifying away from Humira and into a broader